Published on 14 Nov 2022 on Benzinga via Yahoo Finance
Lumos Pharma Says Growth Hormone Deficiency Trial Meet Expectations
Lumos Pharma Inc (NASDAQ: LUMO) announced interim results from its Phase 2 OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial of oral LUM-201 for moderate (idiopathic) pediatric growth hormone deficiency (PGHD).The mean (median) AHV at six months is shown below for each of the four treatment arms:7.26 (7.71) cm/year in the 0.8 mg/kg/day LUM-201 arm (n=11)8.57 (8.61) cm/year in the 1.6 mg/kg/day LUM-201 arm (n=10)7.77 (8.11) cm/year in the 3.2 mg/kg/day LUM-201 arm (n=10)11.05 (10.48) cm/year in the rhGH arm (n=10)Interim results for approximately 50% enrollment (n=41) of OraGrowtH210 Trial demonstrated a mean annualized height velocity (AHV) of 8.6 cm at six months for 1.6 mg/kg/day LUM-201, in line with 8.3 cm AHV expected from historical database comparisons.The company noted that the unexpected growth was likely due to the presence of two of the youngest subjects in the rhGH cohort known to show a robust growth response and other imbalances in several baseline characteristics.The company believes the imbalance in age will even out as enrollment progresses.OraGrowtH210 Trial is now ~80% enrolled, and the company continues to anticipate primary outcome readout with all 80 subjects at six months in 2H 2023.Lumos ended Q3 with a cash balance of $73.7 million, providing a runway into Q2 2024.Price Action: LUMO shares are down 21.20% at $7.02 on the last check Monday.
See more from Benzinga